Panelists discuss how SGLT2 inhibitors evolved from diabetes medications to become foundational heart failure therapy with class I recommendations across the ejection fraction spectrum, providing ...
As a class, sodium–glucose transporter 2 inhibitors are novel drugs initially developed for glycemic control in patients with type 2 diabetes. [Cowie MR, et al. Nat Rev Cardiol. 2020;1a] Their primary ...
In the past several years, major heart failure guidelines have undergone a significant shift: SGLT2 inhibitors are now considered foundational therapy for patients with reduced or preserved ejection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results